An Update of Urine and Blood Metabolomics in Chronic Kidney Disease

References

• Bouatra S , AziatF, MandalRet al. The human urine metabolome. PloS ONE8(9), e73076 (2013).
   PubMed Web of Science ®Google Scholar
• Patti GJ , YanesO, SiuzdakG. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol.13(4), 263 (2012).
   PubMed Web of Science ®Google Scholar
• Turi KN , Romick-RosendaleL, RyckmanKK, HartertTV. A review of metabolomics approaches and their application in identifying causal pathways of childhood asthma. J. Allergy. Clin. Immunol.141(4), 1191–1201 (2018).
   PubMed Web of Science ®Google Scholar
• Khamis MM , AdamkoDJ, El-AneedA. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass. Spectrom. Rev.36(2), 115–134 (2017).
   PubMed Web of Science ®Google Scholar
• Kettunen J , TukiainenT, SarinA-Pet al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet.44(3), 269 (2012).
   PubMed Web of Science ®Google Scholar
• López-López Á , López-GonzálvezÁ, Barker-TejedaTC, BarbasC. A review of validated biomarkers obtained through metabolomics. Expert. Rev. Mol. Diagn.18(6), 557–575 (2018).
   PubMed Web of Science ®Google Scholar
• Dettmer K , AronovPA, HammockBD. Mass spectrometry-based metabolomics. Mass. Spectrom. Rev.26(1), 51–78 (2007).
   PubMed Web of Science ®Google Scholar
• Roberts LD , SouzaAL, GersztenRE, ClishCB. Targeted metabolomics. Curr. Protoc. Mol.98(1), 30–32 (2012).
   Google Scholar
• Ioannidis JP , KhouryMJ. Improving validation practices in “omics” research. Science334(6060), 1230–1232 (2011).
   PubMed Web of Science ®Google Scholar
• Johnson CH , IvanisevicJ, SiuzdakG. Metabolomics: beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell Biol.17(7), 451 (2016).
   PubMed Web of Science ®Google Scholar
• Emwas A-HM . The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. Methods. Mol. Biol.1277, 161–193 (2015).
   PubMedGoogle Scholar
• Hocher B , AdamskiJ. Metabolomics for clinical use and research in chronic kidney disease. Nat. Rev. Nephrol.13(5), 269 (2017).
   PubMed Web of Science ®Google Scholar
• Wilmes A , LimoncielA, AschauerLet al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J. Proteomics.79, 180–194 (2013).
   PubMed Web of Science ®Google Scholar
• Ussher JR , ElmariahS, GersztenRE, DyckJR. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J. Am. Coll. Cardiol.68(25), 2850–2870 (2016).
   PubMed Web of Science ®Google Scholar
• Boelaert J , LynenF, GlorieuxG, SchepersE, NeirynckN, VanholderR. Metabolic profiling of human plasma and urine in chronic kidney disease by hydrophilic interaction liquid chromatography coupled with time-of-flight mass spectrometry: a pilot study. Anal. Bioanal. Chem.409(8), 2201–2211 (2017).
   PubMed Web of Science ®Google Scholar
• Jha V , Garcia-GarciaG, IsekiKet al. Chronic kidney disease: global dimension and perspectives. Lancet382(9888), 260–272 (2013).
   PubMed Web of Science ®Google Scholar
• Eddy AA . Progression in chronic kidney disease. Adv Chronic Kidney Dis.12(4), 353–365 (2005).
   PubMed Web of Science ®Google Scholar
• Hill NR , FatobaST, OkeJLet al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PloS ONE11(7), e0158765 (2016).
   PubMed Web of Science ®Google Scholar
• Chen D-Q , CaoG, ChenHet al. Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/β-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease. Redox. Biol.12, 505–521 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang ZH , ChenH, VaziriNDet al. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. J. Proteome Res.15(10), 3802–3812 (2016).
   PubMed Web of Science ®Google Scholar
• Niewczas MA , SirichTL, MathewAVet al. Uremic solutes and risk of end-stage renal disease in Type 2 diabetes: metabolomic study. Kidney. Int.85(5), 1214–1224 (2014).
   PubMed Web of Science ®Google Scholar
• Kienana M , LydieND, Jean-MichelHet al. Elucidating time-dependent changes in the urinary metabolome of renal transplant patients by a combined 1H NMR and GC–MS approach. Mol. Biosyst.11(9), 2493–2510 (2015).
   PubMedGoogle Scholar
• Sharma K , KarlB, MathewAVet al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J. Am. Soc. Nephrol.24(11), 1901–1912 (2013).
   PubMed Web of Science ®Google Scholar
• Qi S , OuyangX, WangL, PengW, WenJ, DaiY. A Pilot metabolic profiling study in serum of patients with chronic kidney disease based on 1H-NMR-spectroscopy. Clin. Transl. Sci.5(5), 379–385 (2012).
   PubMed Web of Science ®Google Scholar
• Posada-Ayala M , ZubiriI, Martin-LorenzoMet al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int.85(1), 103–111 (2014).
   PubMed Web of Science ®Google Scholar
• Gil R , HeinzmannS, WörmannKet al. FP292 non-targeted metabolomics approaches for elucidation of novel diagnostic markers in chronic kidney disease. Nephrol. Dial. Transplant.30(Suppl. 3), iii164–iii165 (2015).
   Google Scholar
• Toyohara T , AkiyamaY, SuzukiTet al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens. Res.33(9), 944 (2010).
   PubMed Web of Science ®Google Scholar
• Goek ON , PrehnC, SekulaPet al. Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol. Dial. Transplant.28(8), 2131–2138 (2013).
   PubMed Web of Science ®Google Scholar
• Hirayama A , NakashimaE, SugimotoMet al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal. Bioanal. Chem.404(10), 3101–3109 (2012).
   PubMed Web of Science ®Google Scholar
• Pena M , LambersHeerspink H, HellemonsMet al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet. Med.31(9), 1138–1147 (2014).
   PubMed Web of Science ®Google Scholar
• Shah VO , TownsendRR, FeldmanHI, PappanKL, KensickiE, Vander JagtDL. Plasma metabolomic profiles in different stages of CKD. Clin. J. Am. Soc. Nephrol.8(3), 363–370 (2013).
   PubMed Web of Science ®Google Scholar
• Benito S , SánchezA, UncetaNet al. LC–QTOF–MS-based targeted metabolomics of arginine–creatine metabolic pathway-related compounds in plasma: application to identify potential biomarkers in pediatric chronic kidney disease. Anal. Bioanal. Chem.408(3), 747–760 (2016).
   PubMed Web of Science ®Google Scholar
• Afshinnia F , RajendiranTM, SoniTet al. Impaired β-oxidation and altered complex lipid fatty acid partitioning with advancing CKD. J. Am. Soc. Nephrol.29(1), 295–306 (2018).
   PubMed Web of Science ®Google Scholar
• Han LD , XiaJF, LiangQLet al. Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography–mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal. Chim. Acta689(1), 85–91 (2011).
   PubMed Web of Science ®Google Scholar
• Wang L , HuC, LiuSet al. Plasma lipidomics investigation of hemodialysis effects by using liquid chromatography–mass spectrometry. J. Proteome. Res.15(6), 1986–1994 (2016).
   PubMed Web of Science ®Google Scholar
• Emwas A-HM , SalekRM, GriffinJL, MerzabanJ. NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics9(5), 1048–1072 (2013).
   Web of Science ®Google Scholar
• Markley JL , BrüschweilerR, EdisonASet al. The future of NMR-based metabolomics. Curr. Opin. Biotechnol.43, 34–40 (2017).
   PubMed Web of Science ®Google Scholar
• Daly RA , BortonMA, WilkinsMJet al. Microbial metabolisms in a 2.5-km-deep ecosystem created by hydraulic fracturing in shales. Nat. Microbiol.1(10), 16146 (2016).
   PubMed Web of Science ®Google Scholar
• Bingol K . Recent advances in targeted and untargeted metabolomics by NMR and MS/NMR methods. High-Throughput7(2), 9 (2018).
   PubMedGoogle Scholar
• McKay RT . How the 1D-NOESY suppresses solvent signal in metabonomics NMR spectroscopy: an examination of the pulse sequence components and evolution. Concepts. Magn. Reson. Part A38(5), 197–220 (2011).
   Google Scholar
• Kalantari S , NafarM, SamavatSet al.. 1H NMR-based metabolomics exploring urinary biomarkers correlated with proteinuria in focal segmental glomerulosclerosis: a pilot study. Magn. Reson. Chem.54(10), 821–826 (2016).
   PubMed Web of Science ®Google Scholar
• Sandusky P , RafteryD. Use of selective TOCSY NMR experiments for quantifying minor components in complex mixtures: application to the metabonomics of amino acids in honey. Anal. Chem.77(8), 2455–2463 (2005).
   PubMed Web of Science ®Google Scholar
• Xi Y , DeRopp JS, ViantMR, WoodruffDL, YuP. Automated screening for metabolites in complex mixtures using 2D COSY NMR spectroscopy. Metabolomics2(4), 221–233 (2006).
   Web of Science ®Google Scholar
• Mannina L , SobolevA, CapitaniDet al. NMR metabolic profiling of organic and aqueous sea bass extracts: implications in the discrimination of wild and cultured sea bass. Talanta77(1), 433–444 (2008).
   PubMed Web of Science ®Google Scholar
• Gowda GN , DjukovicD. Overview of mass spectrometry-based metabolomics: opportunities and challenges. Methods Mol Biol.1198, 3–12 (2014).
   PubMedGoogle Scholar
• Sparkman OD , PentonZ, KitsonFG. Gas Chromatography and Mass Spectrometry: A Practical Guide. Academic Press, USA (2011).
   Google Scholar
• Zhao YY , ChengXL, VaziriND, LiuS, LinRC. UPLC–based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clin. Biochem.47(15), 16–26 (2014).
   PubMed Web of Science ®Google Scholar
• Zhou B , XiaoJF, TuliL, RessomHW. LC–MS-based metabolomics. Mol. Biosyst.8(2), 470–481 (2012).
   PubMed Web of Science ®Google Scholar
• Bajad SU , LuW, KimballEH, YuanJ, PetersonC, RabinowitzJD. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography–tandem mass spectrometry. J. Chromatogr. A1125(1), 76–88 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao YY , ShenX, ChengXL, WeiF, BaiX, LinRC. Urinary metabonomics study on the protective effects of ergosta-4, 6, 8 (14), 22-tetraen-3-one on chronic renal failure in rats using UPLC Q-TOF/MS and a novel MSE data collection technique. Process Biochem.47(12), 1980–1987 (2012).
   Web of Science ®Google Scholar
• Wrona M , MaurialaT, BatemanKP, Mortishire-SmithRJ, O'ConnorD. ‘All-in-one’ analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid. Commun. Mass. Spectrom.19(18), 2597–2602 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao YY , LiuJ, ChengXL, BaiX, LinRC. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin. Chim. Acta.413(5–6), 642–649 (2012).
   PubMed Web of Science ®Google Scholar
• Zhao YY , FengYL, BaiX, TanXJ, LinRC, MeiQ. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. PloS ONE8(3), e59617 (2013).
   PubMed Web of Science ®Google Scholar
• Zhao YY , ChenH, TianT, ChenDQ, BaiX, WeiF. A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC–QTOF/HDMS. PLoS ONE9(12), e115467 (2014).
   PubMed Web of Science ®Google Scholar
• Zhao YY , ChengXL, WeiFet al. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-β1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MSE. J. Proteome Res.12(2), 692–703 (2013).
   PubMed Web of Science ®Google Scholar
• Zhao YY , LinRC. UPLC–MSE application in disease biomarker discovery: the discoveries in proteomics to metabolomics. Chem. Biol. Interact.215, 7–16 (2014).
   PubMed Web of Science ®Google Scholar
• Psychogios N , HauDD, PengJet al. The human serum metabolome. PloS ONE6(2), e16957 (2011).
   PubMed Web of Science ®Google Scholar
• West JB . Study Guide and Self-examination Review for Best and Taylor's Physiological Basis of Medical Practice. Williams & Wilkins, USA (1985).
   Google Scholar
• Fischer S . Analysis of cardiovascular eicosanoids in man with special reference to HPLC. Chromatographia22(7–12), 416–420 (1986).
   Web of Science ®Google Scholar
• Yu Z , KastenmüllerG, HeYet al. Differences between human plasma and serum metabolite profiles. PloS ONE6(7), e21230 (2011).
   PubMed Web of Science ®Google Scholar
• Liu L , AaJ, WangGet al. Differences in metabolite profile between blood plasma and serum. Anal. Biochem.406(2), 105–112 (2010).
   PubMed Web of Science ®Google Scholar
• Suarez-Diez M , AdamJ, AdamskiJet al. Plasma and serum metabolite association networks: comparability within and between studies using NMR and MS profiling. J. Proteome. Res.16(7), 2547–2559 (2017).
   PubMed Web of Science ®Google Scholar
• Boudah S , OlivierM-F, Aros-CaltSet al. Annotation of the human serum metabolome by coupling three liquid chromatography methods to high-resolution mass spectrometry. J. Chromatogr. B966, 34–47 (2014).
   PubMed Web of Science ®Google Scholar
• Tizianello A , DeFerrari G, GaribottoG, GurreriG, RobaudoC. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J. Clin. Invest.65(5), 1162–1173 (1980).
   PubMed Web of Science ®Google Scholar
• Rhee EP , ClishCB, GhorbaniAet al. A combined epidemiologic and metabolomic approach improves CKD prediction. J. Am. Soc. Nephrol.24(8), 1330–1338 (2013).
   PubMed Web of Science ®Google Scholar
• Kalim S , RheeEP. An overview of renal metabolomics. Kidney. Int.91(1), 61–69 (2017).
   PubMed Web of Science ®Google Scholar
• Debnath S , VelagapudiC, RedusLet al. Tryptophan metabolism in patients with chronic kidney disease secondary to Type 2 diabetes: relationship to inflammatory markers. Int. J. Tryptophan. Res.10, 1178646917694600 (2017).
   PubMedGoogle Scholar
• Wang Y , LiuH, McKenzieGet al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med.16(3), 279 (2010).
   PubMed Web of Science ®Google Scholar
• Roshanravan B , ZelnickLR, DjucovicDet al. Chronic kidney disease attenuates the plasma metabolome response to insulin. JCI Insight.3(16), 122219 (2018).
   PubMed Web of Science ®Google Scholar
• Kimura T , YasudaK, YamamotoRet al. Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling. Sci. Rep.6, 26138 (2016).
   PubMed Web of Science ®Google Scholar
• Kobayashi T , YoshidaT, FujisawaTet al. A metabolomics-based approach for predicting stages of chronic kidney disease. Biochem. Biophys. Res. Commun.445(2), 412–416 (2014).
   PubMed Web of Science ®Google Scholar
• Karu N , McKercherC, NicholsDSet al. Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian chronic kidney disease pilot study. BMC Nephrol.17(1), 171 (2016).
   PubMedGoogle Scholar
• Niewczas MA , MathewAV, CroallSet al. Circulating modified metabolites and a risk of ESRD in patients with Type 1 diabetes and chronic kidney disease. Diabetes. Care.40 (3), 383–390 (2017).
   PubMed Web of Science ®Google Scholar
• Mika A , WojtowiczW, ZąbekAet al. Application of nuclear magnetic resonance spectroscopy for the detection of metabolic disorders in patients with moderate kidney insufficiency. J. Pharm. Biomed. Anal.149, 1–8 (2018).
   PubMed Web of Science ®Google Scholar
• Benito S , Sanchez-OrtegaA, UncetaNet al. Untargeted metabolomics for plasma biomarker discovery for early chronic kidney disease diagnosis in pediatric patients using LC–QTOF–MS. The Analyst143(18), 4448–4458 (2018).
   PubMed Web of Science ®Google Scholar
• Rysz J , Gluba-BrzózkaA, FranczykB, JabłonowskiZ, Ciałkowska-RyszA. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Int. J. Mol. Sci.18(8), 1702 (2017).
   PubMed Web of Science ®Google Scholar
• Barrios C , SpectorTD, MenniC. Blood, urine and faecal metabolite profiles in the study of adult renal disease. Arch. Biochem. Biophys.589, 81–92 (2016).
   PubMed Web of Science ®Google Scholar
• Zuppi C , MessanaI, ForniFet al. 1H NMR spectra of normal urines: reference ranges of the major metabolites. Clin. Chim. Acta265(1), 85–97 (1997).
   PubMed Web of Science ®Google Scholar
• Slupsky CM , RankinKN, WagnerJet al. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal. Chem.79(18), 6995–7004 (2007).
   PubMed Web of Science ®Google Scholar
• Mandal R , GuoAC, ChaudharyKKet al. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med.4(4), 38 (2012).
   PubMed Web of Science ®Google Scholar
• Takeda I , StretchC, BarnabyPet al. Understanding the human salivary metabolome. NMR Biomedicine22(6), 577–584 (2009).
   PubMed Web of Science ®Google Scholar
• Kielstein A , TsikasD, GallowayGP, MendelsonJE. Asymmetric dimethylarginine (ADMA) – a modulator of nociception in opiate tolerance and addiction?Nitric Oxide17(2), 55–59 (2007).
   PubMed Web of Science ®Google Scholar
• Mcbride AE , SilverPA. State of the arg: protein methylation at arginine comes of age. Cell106(1), 5–8 (2001).
   PubMed Web of Science ®Google Scholar
• Achan V , BroadheadM, MalakiMet al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol.23(8), 1455–1459 (2003).
   PubMed Web of Science ®Google Scholar
• Kielstein JT , FliserD. The past, presence and future of ADMA in nephrology. Nephrol. Ther.3(2), 47–54 (2007).
   PubMed Web of Science ®Google Scholar
• Leone A , MoncadaS, VallanceP, CalverA, CollierJ. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet339(8793), 572–575 (1992).
   PubMed Web of Science ®Google Scholar
• Osamu S , MasatoT, TsuyoshiM. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice. Involvement of renin-angiotensin system and oxidative stress. Arterioscler. Thromb. Vasc. Biol24, 1682–1688 (2004).
   PubMed Web of Science ®Google Scholar
• Wang D , GillPS, ChabrashviliTet al. Isoform-specific regulation by NG, NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ. Res.101(6), 627–635 (2007).
   PubMed Web of Science ®Google Scholar
• Fleck C , JanzA, SchweitzerF, KargeE, SchwertfegerM, SteinG. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney. Int.59, S14–S18 (2001).
   Web of Science ®Google Scholar
• Baylis C . Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat. Rev. Nephrol.2(4), 209 (2006).
   Google Scholar
• Raptis V , KapoulasS, GrekasD. Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology18(1), 11–21 (2013).
   PubMed Web of Science ®Google Scholar
• Zoccali C , KielsteinJT. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?Curr. Opin. Nephrol. Hypertens.15(3), 314–320 (2006).
   PubMed Web of Science ®Google Scholar
• Zoccali C , BenedettoFA, MaasRet al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol.13(2), 490–496 (2002).
   PubMed Web of Science ®Google Scholar
• Lundin U . Biomarker discovery in diabetic nephropathy by targeted metabolomics [Masters thesis]. Linköping University, Linköping, Sweden (2008).
   Google Scholar
• Kuo HC , HsuCN, HuangCF, LoMH, ChienSJ, TainYL. Urinary arginine methylation index associated with ambulatory blood pressure abnormalities in children with chronic kidney disease. J. Am. Soc. Hypertens.6(6), 385–392 (2012).
   PubMed Web of Science ®Google Scholar
• Duranton F , LundinU, GayrardNet al. Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. Clin. J. Am. Soc. Nephrol.9(1), 37–45 (2014).
   PubMed Web of Science ®Google Scholar
• Kanzelmeyer NK , PapeL, Chobanyan-JürgensKet al. L-arginine/NO pathway is altered in children with haemolytic-uraemic syndrome (HUS). Oxid. Med. Cell. Longev.2014, Article ID 203512 (2014).
   PubMed Web of Science ®Google Scholar
• Mihout F , ShwekeN, BigéNet al. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis. J. Pathol.223(1), 37–45 (2011).
   PubMed Web of Science ®Google Scholar
• Benito S , Sanchez-OrtegaA, UncetaNet al. Plasma biomarker discovery for early chronic kidney disease diagnosis based on chemometric approaches using LC–QTOF targeted metabolomics data. J. Pharm. Biomed. Anal.149, 46–56 (2018).
   PubMed Web of Science ®Google Scholar
• Breit M , WeinbergerKM. Metabolic biomarkers for chronic kidney disease. Arch. Biochem. Biophys.589, 62–80 (2016).
   PubMed Web of Science ®Google Scholar
• Stubbs JR , HouseJA, OcqueAJet al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J. Am. Soc. Nephrol.27(1), 305–313 (2016).
   PubMed Web of Science ®Google Scholar
• Cho CE , TaesuwanS, MalyshevaOVet al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial. Mol. Nutr. Food. Res.61(1), 1600324 (2017).
   Web of Science ®Google Scholar
• De Filippis F , PellegriniN, VanniniLet al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut65(11), 1812–1821 (2016).
   PubMed Web of Science ®Google Scholar
• Lang D , YeungC, PeterRet al. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem. Pharmacol.56(8), 1005–1012 (1998).
   PubMed Web of Science ®Google Scholar
• Mitchell S , ZhangA, NobletJ, GillespieS, JonesN, SmithR. Metabolic disposition of [14C]-trimethylamine N-oxide in rat: variation with dose and route of administration. Xenobiotica27(11), 1187–1197 (1997).
   PubMed Web of Science ®Google Scholar
• Cho CE , CaudillMA. Trimethylamine-N-oxide: friend, foe, or simply caught in the cross-fire?Trends. Endocrinol. Metab.28(2), 121–130 (2017).
   PubMed Web of Science ®Google Scholar
• Yancey PH . Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J. Exp. Biol.208(15), 2819–2830 (2005).
   PubMed Web of Science ®Google Scholar
• Kumemoto R , YusaK, ShibayamaT, HatoriK. Trimethylamine N-oxide suppresses the activity of the actomyosin motor. Biochim. Biophys. Acta1820(10), 1597–1604 (2012).
   PubMed Web of Science ®Google Scholar
• Lin T-Y , TimasheffSN. Why do some organisms use a urea-methylamine mixture as osmolyte? Thermodynamic compensation of urea and trimethylamine N-oxide interactions with protein. Biochemistry33(42), 12695–12701 (1994).
   PubMed Web of Science ®Google Scholar
• Ma J , PazosIM, GaiF. Microscopic insights into the protein-stabilizing effect of trimethylamine N-oxide (TMAO). Proc. Natil Acad. Sci. USA111(23), 8476–8481 (2014).
   PubMed Web of Science ®Google Scholar
• Velasquez MT , RamezaniA, ManalA, RajDS. Trimethylamine N-oxide: the good, the bad and the unknown. Toxins8(11), 326 (2016).
   PubMed Web of Science ®Google Scholar
• Yamamoto S , KazamaJJ, WakamatsuTet al. Removal of uremic toxins by renal replacement therapies: a review of current progress and future perspectives. Ren. Replace. Ther.2(1), 43 (2016).
   Google Scholar
• Bain MA , FaullR, FornasiniG, MilneRW, EvansAM. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol. Dial. Transplant.21(5), 1300–1304 (2006).
   PubMed Web of Science ®Google Scholar
• Missailidis C , HallqvistJ, QureshiARet al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS ONE11(1), e0141738 (2016).
   PubMed Web of Science ®Google Scholar
• Manor O , ZubairN, ConomosMPet al. A multi-omic association study of trimethylamine N-oxide. Cell. Rep.24(4), 935–946 (2018).
   PubMed Web of Science ®Google Scholar
• Xu K-Y , XiaG-H, LuJ-Qet al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci. Rep.7(1), 1445–1445 (2017).
   PubMed Web of Science ®Google Scholar
• Gruppen EG , GarciaE, ConnellyMAet al. TMAO is associated with mortality: impact of modestly impaired renal function. Sci. Rep.7(1), 13781 (2017).
   PubMedGoogle Scholar
• Nakajima T , MatsuokaY, KakimotoY. Isolation and identification of NG-monomethyl NG, NG-dimethyl-and NG, NG-dimethylarginine from the hydrolysate of proteins of bovine brain. Biochim. Biophys. Acta230(2), 212–222 (1971).
   PubMedGoogle Scholar
• Morales Y , CáceresT, MayK, HevelJM. Biochemistry and regulation of the protein arginine methyltransferases (PRMTs). Arch. Biochem. Biophys.590, 138–152 (2016).
   PubMed Web of Science ®Google Scholar
• Tain YL , HsuCN. Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins9(3), 92 (2017).
   PubMed Web of Science ®Google Scholar
• Kakimoto Y , AkazawaS. Isolation and identification of NG, NG-and NG, N'G-dimethylarginine, Nε-mono-, di-, and trimethyllysine, and glucosylgalactosyl-and galactosyl-δ-hydroxylysine from human urine. J. Biol. Chem.245(21), 5751–5758 (1970).
   PubMed Web of Science ®Google Scholar
• Mcdermott J . Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem. J.154(1), 179–184 (1976).
   PubMed Web of Science ®Google Scholar
• Bode-Böger SM , ScaleraF, KielsteinJTet al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J. Am. Soc. Nephrol.17(4), 1128–1134 (2006).
   PubMed Web of Science ®Google Scholar
• Closs EI , BashaFZ, HabermeierA, FörstermannU. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide1(1), 65–73 (1997).
   PubMed Web of Science ®Google Scholar
• Kielstein JT , SalpeterSR, Bode-BoegerSM, CookeJP, FliserD. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function – a meta-analysis. Nephrol. Dial. Transplant.21(9), 2446–2451 (2006).
   PubMed Web of Science ®Google Scholar
• MaCallister R , RambausekM, VallanceP, WilliamsD, HoffmannKH, RitzE. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol. Dial. Transplant.11(12), 2449–2452 (1996).
   PubMed Web of Science ®Google Scholar
• El-Sadek AE , BeheryEG, AzabAAet al. Arginine dimethylation products in pediatric patients with chronic kidney disease. Ann. Med. Surg.9, 22–27 (2016).
   PubMedGoogle Scholar
• El-Khoury JM , BunchDR, HuB, PaytoD, ReineksEZ, WangS. Comparison of symmetric dimethylarginine with creatinine, cystatin C and their eGFR equations as markers of kidney function. Clin. Biochem.49(15), 1140–1143 (2016).
   PubMed Web of Science ®Google Scholar
• Torrent E , PlanellasM, OrdeixL, PastorJ, RodonJ, Solano-GallegoL. Serum symmetric dimethylarginine as an early marker of excretory dysfunction in canine leishmaniosis (L. infantum) induced nephropathy. Vet. Med. Int. 2018, 7517359 (2018).
   PubMedGoogle Scholar
• Peterson ME , VarelaFV, RishniwM, PolzinDJ. Evaluation of serum symmetric dimethylarginine concentration as a marker for masked chronic kidney disease in cats with hyperthyroidism. J. Vet. Intern. Med.32(1), 295–304 (2018).
   PubMed Web of Science ®Google Scholar
• Van Den Brand JA , MutsaersHA, Van ZuilenADet al. Uremic solutes in chronic kidney disease and their role in progression. PLoS ONE.11(12), e0168117 (2016).
   PubMed Web of Science ®Google Scholar
• Vanholder R , DeSmet R, GlorieuxGet al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney. Int.63(5), 1934–1943 (2003).
   PubMed Web of Science ®Google Scholar
• Duranton F , CohenG, DeSmet Ret al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol.23(7), 1258–1270 (2012).
   PubMed Web of Science ®Google Scholar
• Kim SH , YuMA, RyuES, JangYH, KangDH. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest.92(4), 488–498 (2012).
   PubMed Web of Science ®Google Scholar
• Mutsaers HA , Caetano-PintoP, SeegersAEet al. Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: implications for chronic kidney disease pathophysiology. Toxicol. In Vitro29(7), 1868–1877 (2015).
   PubMed Web of Science ®Google Scholar
• Owada S , MaebaT, SuganoYet al. Spherical carbon adsorbent (AST-120) protects deterioration of renal function in chronic kidney disease rats through inhibition of reactive oxygen species production from mitochondria and reduction of serum lipid peroxidation. Nephron. Exp. Nephrol.115(4), e101–111 (2010).
   PubMedGoogle Scholar
• Mutsaers HA , WilmerMJ, ReijndersDet al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim. Biophys. Acta.1832(1), 142–150 (2013).
   PubMed Web of Science ®Google Scholar
• Taes YE , MarescauB, DeVriese Aet al. Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. Nephrol. Dial. Transplant.23(4), 1330–1335 (2008).
   PubMed Web of Science ®Google Scholar
• Muller C , EisenbrandG, GradingerMet al. Effects of hemodialysis, dialyser type and iron infusion on oxidative stress in uremic patients. Free. Radic. Res.38(10), 1093–1100 (2004).
   PubMed Web of Science ®Google Scholar
• Ficheux A , GayrardN, SzwarcIet al. The use of SDS-PAGE scanning of spent dialysate to assess uraemic toxin removal by dialysis. Nephrol. Dial. Transplant.26(7), 2281–2289 (2011).
   PubMed Web of Science ®Google Scholar
• Moon SJ , KimDK, ChangJHet al. The impact of dialysis modality on skin hyperpigmentation in haemodialysis patients. Nephrol. Dial. Transplant.24(9), 2803–2809 (2009).
   PubMed Web of Science ®Google Scholar
• Rhee EP , SouzaA, FarrellLet al. Metabolite profiling identifies markers of uremia. J. Am. Soc. Nephrol.21(6), 1041–1051 (2010).
   PubMed Web of Science ®Google Scholar
• Meyer TW , HostetterTH. Uremic solutes from colon microbes. Kidney. Int.81(10), 949–954 (2012).
   PubMed Web of Science ®Google Scholar
• Meijers BK , DeLoor H, BammensB, VerbekeK, VanrenterghemY, EvenepoelP. p-cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin. J. Am. Soc. Nephrol.4(12), 1932–1938 (2009).
   PubMed Web of Science ®Google Scholar
• Poveda J , Sanchez-NinoMD, GlorieuxGet al. p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol. Dial. Transplant29(1), 56–64 (2014).
   PubMed Web of Science ®Google Scholar
• Sun CY , ChangSC, WuMS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney. Int.81(7), 640–650 (2012).
   PubMed Web of Science ®Google Scholar
• Koppe L , PillonNJ, VellaREet al. p-cresyl sulfate promotes insulin resistance associated with CKD. J. Am. Soc. Nephrol.24(1), 88–99 (2013).
   PubMed Web of Science ®Google Scholar
• Wikoff WR , AnforaAT, LiuJet al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA106(10), 3698–3703 (2009).
   PubMed Web of Science ®Google Scholar
• Aronov PA , LuoFJ, PlummerNSet al. Colonic contribution to uremic solutes. J. Am. Soc. Nephrol.22(9), 1769–1776 (2011).
   PubMed Web of Science ®Google Scholar
• Hung SC , KuoKL, WuCC, TarngDC. Indoxyl sulfate: a novel cardiovascular risk factor in chronic kidney disease. J. Am. Heart. Assoc.6(2), e005022 (2017).
   Web of Science ®Google Scholar
• Lin CJ , LiuHL, PanCFet al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch. Med. Res.43(6), 451–456 (2012).
   PubMed Web of Science ®Google Scholar
• Yu M , KimYJ, KangDH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin. J. Am. Soc. Nephrol.6(1), 30–39 (2011).
   PubMed Web of Science ®Google Scholar
• Chitalia VC , ShivannaS, MartorellJet al. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation127(3), 365–376 (2013).
   PubMed Web of Science ®Google Scholar
• Ito S , OsakaM, HiguchiY, NishijimaF, IshiiH, YoshidaM. Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. J. Biol. Chem.285(50), 38869–38875 (2010).
   PubMed Web of Science ®Google Scholar
• Lekawanvijit S , AdrahtasA, KellyDJ, KompaAR, WangBH, KrumH. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?Eur. Heart. J.31(14), 1771–1779 (2010).
   PubMed Web of Science ®Google Scholar
• Sun CY , ChangSC, WuMS. Uremic toxins induce kidney fibrosis by activating intrarenal renin–angiotensin–aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE.7(3), e34026 (2012).
   PubMed Web of Science ®Google Scholar
• Shimizu H , BolatiD, HigashiyamaY, NishijimaF, ShimizuK, NiwaT. Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-kappaB, p53, ERK, and JNK in proximal tubular cells. Life. Sci.90(13–14), 525–530 (2012).
   PubMed Web of Science ®Google Scholar
• Takada T , YamamotoT, MatsuoHet al. Identification of ABCG2 as an exporter of uremic toxin indoxyl sulfate in mice and as a crucial factor influencing CKD progression. Sci. Rep.8(1), 11147 (2018).
   PubMedGoogle Scholar
• Jourde-Chiche N , DouL, CeriniC, Dignat-GeorgeF, VanholderR, BrunetP. Protein-bound toxins – update 2009. Semin. Dial.22(4), 334–339 (2009).
   PubMed Web of Science ®Google Scholar
• Brito JS , BorgesNA, EsgalhadoM, MaglianoDC, SoulageCO, MafraD. Aryl hydrocarbon receptor activation in chronic kidney disease: role of uremic toxins. Nephron.137(1), 1–7 (2017).
   PubMed Web of Science ®Google Scholar
• Dou L , SalleeM, CeriniCet al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J. Am. Soc. Nephrol.26(4), 876–887 (2015).
   PubMed Web of Science ®Google Scholar
• Borges NA , BarrosAF, NakaoLS, DolengaCJ, FouqueD, MafraD. Protein-bound uremic toxins from gut microbiota and inflammatory markers in chronic kidney disease. J. Ren. Nutr.26(6), 396–400 (2016).
   PubMed Web of Science ®Google Scholar
• Tanaka H , SirichTL, PlummerNS, WeaverDS, MeyerTW. An enlarged profile of uremic solutes. PLoS ONE10(8), e0135657 (2015).
   PubMed Web of Science ®Google Scholar
• Silva RE , BaldimJL, Chagas-PaulaDAet al. Predictive metabolomic signatures of end-stage renal disease: a multivariate analysis of population-based data. Biochimie152, 14–30 (2018).
   PubMed Web of Science ®Google Scholar
• Zhao YY , ChengXL, WeiFet al. Serum metabonomics study of adenine-induced chronic renal failure in rats by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers17(1), 48–55 (2012).
   PubMed Web of Science ®Google Scholar
• Zhao YY , ChengXL, CuiJHet al. Effect of ergosta-4, 6, 8 (14), 22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clin. Chim. Acta413(19–20), 1438–1445 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang ZH , WeiF, VaziriNDet al. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Sci. Rep.5, 14472 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang ZH , ChenH, VaziriNDet al. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. J. Proteome. Res.15(10), 3802–3812 (2016).
   PubMed Web of Science ®Google Scholar
• Velenosi TJ , HennopA, FeereDAet al. Untargeted plasma and tissue metabolomics in rats with chronic kidney disease given AST-120. Sci. Rep.6, 22526 (2016).
   PubMed Web of Science ®Google Scholar
• Mathew AV , ZengL, ByunJ, PennathurS. Metabolomic profiling of arginine metabolome links altered methylation to chronic kidney disease accelerated atherosclerosis. J. Proteomics Bioinform.Suppl 14, pii: 001 (2015).
   PubMedGoogle Scholar
• Kim JA , ChoiHJ, KwonYK, RyuDH, KwonTH, HwangGS. 1H NMR-based metabolite profiling of plasma in a rat model of chronic kidney disease. PLoS ONE.9(1), e85445 (2014).
   PubMed Web of Science ®Google Scholar
• Titan SM , VenturiniG, PadilhaKet al. Metabolites related to eGFR: Evaluation of candidate molecules for GFR estimation using untargeted metabolomics. Clin. Chim. Acta.489, 242–248 (2019).
   PubMed Web of Science ®Google Scholar
• Sekula P , GoekON, QuayeLet al. A metabolome-wide association study of kidney function and disease in the general population. J. Am. Soc. Nephrol.27(4), 1175–1188 (2016).
   PubMed Web of Science ®Google Scholar
• Yu B , ZhengY, NettletonJA, AlexanderD, CoreshJ, BoerwinkleE. Serum metabolomic profiling and incident CKD among African Americans. Clin. J. Am. Soc. Nephrol.9(8), 1410–1417 (2014).
   PubMed Web of Science ®Google Scholar
• Tavares G , VenturiniG, PadilhaKet al. 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics. Metabolomics14(4), 39 (2018).
   PubMed Web of Science ®Google Scholar
• Levin A , TonelliM, BonventreJet al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet390(10105), 1888–1917 (2017).
   PubMed Web of Science ®Google Scholar